A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00002131 |
Recruitment Status
:
Completed
First Posted
: August 31, 2001
Last Update Posted
: June 24, 2005
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sarcoma, Kaposi HIV Infections | Drug: Vesnarinone | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 28 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria
Concurrent Medication:
Allowed:
- Chemoprophylaxis for Pneumocystis carinii, candida, and mycobacteria.
- Acyclovir as acute treatment for herpes outbreaks.
Concurrent Treatment:
Allowed:
- Limited electron-beam radiation therapy to non-marker lesions for treatment of Kaposi's sarcoma.
Patients must have:
- Documented HIV infection.
- Kaposi's sarcoma.
- No current constitutional signs of HIV disease or AIDS-defining conditions other than Kaposi's sarcoma.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Active malignancy other than Kaposi's sarcoma, cutaneous basal cell carcinoma, or in situ carcinoma of the cervix.
- Current significant cardiac disease or anomaly (including prolonged QTC on EKG).
- Abnormal cardio-thoracic ratio on chest x-ray.
Concurrent Medication:
Excluded:
- Antiretroviral agents, including ddI, ddC, AZT, and d4T.
- Immunosuppressive agents.
- Investigational HIV drugs/therapies including vaccines (except those on treatment IND for approved indications).
- Other anti-Kaposi's sarcoma/HIV drugs.
- Corticosteroids (other than topical).
- Biologic response modifiers.
- Megestrol acetate.
- Agents known to cause neutropenia.
- Trimethoprim/sulfamethoxazole in excess of 160 mg trimethoprim and 800 mg sulfamethoxazole thrice weekly.
- Cytotoxic chemotherapy.
Concurrent Treatment:
Excluded:
- Radiation therapy including electron beam irradiation (other than limited electron-beam radiation to non-marker lesions for treatment of Kaposi's sarcoma).
Patients with the following prior conditions are excluded:
- Prior history of significant cardiac disease or anomaly.
- History of agranulocytosis or severe grade 3 drug-induced neutropenia or documented abnormalities in granulocyte function.
Prior Medication:
Excluded:
- AZT within 14 days prior to study entry.
- Acyclovir as prophylaxis for herpes within 48 hours prior to study entry.
Excluded within 30 days prior to study entry:
- Interferon.
- Biologic response modifiers.
- Cytotoxic chemotherapy.
Prior Treatment:
Excluded within 30 days prior to study entry:
- Blood or cellular blood product. Active illicit drug abuse (specifically cocaine, amyl nitrate, heroin, or other cardioactive agents).

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002131
United States, California | |
UCLA School of Medicine | |
Los Angeles, California, United States, 900121973 | |
United States, Illinois | |
Northwestern Univ Med School | |
Chicago, Illinois, United States, 60611 |
Publications:
ClinicalTrials.gov Identifier: | NCT00002131 History of Changes |
Other Study ID Numbers: |
234D 22-93-254 |
First Posted: | August 31, 2001 Key Record Dates |
Last Update Posted: | June 24, 2005 |
Last Verified: | April 1996 |
Keywords provided by NIH AIDS Clinical Trials Information Service:
Sarcoma, Kaposi Acquired Immunodeficiency Syndrome Antiviral Agents vesnarinone |
Additional relevant MeSH terms:
HIV Infections Sarcoma Sarcoma, Kaposi Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Neoplasms Herpesviridae Infections |
DNA Virus Infections Neoplasms, Vascular Tissue Vesnarinone Adjuvants, Immunologic Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Antiviral Agents Anti-Infective Agents Cardiotonic Agents Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protective Agents |